Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

 
• By Joseph Haas
  
Text Starting Point and yellow pencil on bright background
Now that it has approval in ES, Epizyme will attempt to move Tazverik into larger indications
Scrip Podcast

Have you checked out Scrip podcast?

New episodes every Thursday.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip